131 related articles for article (PubMed ID: 38418189)
21. [The influence of various myelosuppression degrees during neoadjuvant chemotherapy on the curative effect and prognosis of triple-negative breast cancer].
Niu YD; Zhang YW; Zhu RJ; Chu T; Wang L; Wang S; Li YY; Dong Y
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(29):2290-2294. PubMed ID: 35927061
[No Abstract] [Full Text] [Related]
22. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
24. Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.
Gwark SC; Lee HS; Lee Y; Lee SB; Sohn G; Kim J; Chung IY; Ko BS; Kim HJ; Son BH; Ahn JH; Jung KH; Kim SB; Lee HJ; Gong GY; Ahn SH; Lee JW
Ann Surg Oncol; 2019 Jul; 26(7):2166-2174. PubMed ID: 30977015
[TBL] [Abstract][Full Text] [Related]
25. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.
Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103
[TBL] [Abstract][Full Text] [Related]
26. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer.
Liu AN; Sun P; Liu JN; Ma JB; Qu HJ; Zhu H; Yu CY; Zhang LM
Asian Pac J Cancer Prev; 2012; 13(4):1197-201. PubMed ID: 22799305
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer.
Chen Z; Chen X; Zhou E; Chen G; Qian K; Wu X; Miao X; Tang Z
PLoS One; 2014; 9(4):e95475. PubMed ID: 24743335
[TBL] [Abstract][Full Text] [Related]
29. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
30. [Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].
Sun GY; Wang SL; Tang Y; Jin J; Song YW; Liu YP; Wang WH; Fang H; Chen SY; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):352-358. PubMed ID: 29860762
[No Abstract] [Full Text] [Related]
31. The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
Kim HS; Yoo TK; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Apr; 180(2):461-470. PubMed ID: 32020434
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of breast cancer patients with pathologic N3a lymph node stage.
Grassadonia A; Vici P; Gamucci T; Moscetti L; Pizzuti L; Mentuccia L; Iezzi L; Scognamiglio MT; Zilli M; Giampietro J; Graziano V; Natoli C; Tinari N
Breast; 2017 Apr; 32():79-86. PubMed ID: 28064072
[TBL] [Abstract][Full Text] [Related]
33. The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy.
Wu SG; He ZY; Li FY; Wang JJ; Guo J; Lin Q; Guan XX
Chin J Cancer; 2010 Jul; 29(7):668-76. PubMed ID: 20591219
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
[No Abstract] [Full Text] [Related]
35. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
[No Abstract] [Full Text] [Related]
36. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
37. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
39. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Gruber G; Greiner RH; Hlushchuk R; Aebersold DM; Altermatt HJ; Berclaz G; Djonov V
Breast Cancer Res; 2004; 6(3):R191-8. PubMed ID: 15084243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]